AB-3028 not checked

Arsenal Biosciences, Inc.

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Main trialPhase 1/2
“This is a multi-center, open-label Phase 1/2 trial evaluating the safety and efficacy of AB-3028 in subjects with metastatic castration resistant prostate cancer (mCRPC).”In the company’s words, NCT07285694 on ClinicalTrials.gov

Other drugs for Metastatic Castration Resistant Prostate Cancer (mCRPC)

All 25 drugs for Metastatic Castration Resistant Prostate Cancer (mCRPC)

Coming up0

No dates coming up.

Changes2

Last 90 days

Trials1

TrialPhaseCompletesWhat it tests
Phase 1/2Terminated 19 Oct 2026 AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow AB-3028

Following is part of Solo: you see every change to AB-3028 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in